12.09.13
Aurora Spine Corp. received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ZIP minimally invasive interspinous fusion system. ZIP is a minimally invasive spinal fixation device for spinal fusion that was developed as an alternative to the pedicle screw systems prevalent in the market today. The company has launched the ZIP in Europe, where it has already been used in 40 surgeries. The company currently has distribution agreements in place with more than 35 distributors for sales of the ZIP in the United States.
The ZIP features articulating bone anchors, a one-step locking mechanism with no set-screw and a large graft space designed for biologic material, according to the company. It is designed for stabilization during T1-S1 lumbar fusion procedures, specifically for the treatment of degenerative disc disease, spondylolisthesis, spinal tumors and trauma. The ZIP is available in various sizes to accommodate different patient anatomy.
"Receipt of FDA 510(k) clearance for our ZIP MIS interspinous fusion system is a key milestone for Aurora Spine as it allows us to launch the product in the U.S. market. This achievement is a testament to the ongoing dedication and perseverance of our team," said Trent J. Northcutt, president and CEO of Aurora Spine. "I am delighted we have obtained FDA clearance, especially given the overwhelming response for the ZIP device in Europe. This approval paves the way for Aurora Spine to be a leading designer and manufacturer of minimally invasive devices."
Based in Carlsbad, Calif., Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
The ZIP features articulating bone anchors, a one-step locking mechanism with no set-screw and a large graft space designed for biologic material, according to the company. It is designed for stabilization during T1-S1 lumbar fusion procedures, specifically for the treatment of degenerative disc disease, spondylolisthesis, spinal tumors and trauma. The ZIP is available in various sizes to accommodate different patient anatomy.
"Receipt of FDA 510(k) clearance for our ZIP MIS interspinous fusion system is a key milestone for Aurora Spine as it allows us to launch the product in the U.S. market. This achievement is a testament to the ongoing dedication and perseverance of our team," said Trent J. Northcutt, president and CEO of Aurora Spine. "I am delighted we have obtained FDA clearance, especially given the overwhelming response for the ZIP device in Europe. This approval paves the way for Aurora Spine to be a leading designer and manufacturer of minimally invasive devices."
Based in Carlsbad, Calif., Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.